Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons

International Journal of Developmental Neuroscience

Volumn 26, Issue 3-4, 2008, Pages 269-276

  Pizarro, Javier G ^a,c   Yeste Velasco, Marc ^a,c   Rimbau, Victor ^a,c   Casadesús, Gemma ^d   Smith, Mark A ^d   Pallàs, Mercè ^a,c   Folch, Jaume ^b,c   Camins, Antoni ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B65 Neuroblastoma cells; Cerebellar granule cells; H2O2; Lithium; Oxidative stress; SB 415286

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; DICHLORODIHYDROFLUORESCEIN DIACETATE; FLUORESCENT DYE; GLYCOGEN SYNTHASE KINASE 3; HYDROGEN PEROXIDE; LITHIUM; REACTIVE OXYGEN METABOLITE; SERINE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; GRANULE CELL; IMMUNOBLOTTING; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINOPHENOLS; ANIMALS; ANIMALS, NEWBORN; CELL LINE, TUMOR; CELLS, CULTURED; CYTOPROTECTION; ENZYME ACTIVATION; ENZYME INHIBITORS; FLUORESCENT DYES; GLYCOGEN SYNTHASE KINASE 3; HYDROGEN PEROXIDE; INDICATORS AND REAGENTS; LITHIUM; MALEIMIDES; NEUROBLASTOMA; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDANTS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

RATTUS;

EID: 41649088599     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2008.02.002     Document Type: Article

References (36)

1. Aghdam S.Y., and Barger S.W. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection Lessons from lithium. Current Alzheimer Res. 3 (2007) 21-31
2. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408 (2007) 297-315
3. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee C.L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., and Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7 (2000) 793-803
4. Cross D.A., Culbert A.A., Chalmers K.A., Facci L., Skaper S.D., and Reith A.D. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. 77 (2001) 94-102
5. Cui J., Shao L., Young L.T., and Wang J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144 (2007) 1447-1453
6. de Vasconcellos A.P., Nieto F.B., Crema L.M., Diehl L.A., de Almeida L.M., Prediger M.E., da Rocha E.R., and Dalmaz C. Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem. Res. 31 (2006) 1141-1151
7. Engel T., Goni-Oliver P., Lucas J.J., Avila J., and Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99 (2006) 1445-1455
8. Facci L., Stevens D.A., and Skaper S.D. Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport 14 (2003) 1467-1470
9. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., and Quevedo J. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychiat. Neurosci. 31 (2006) 326-332
10. Ghribi O., Herman M.M., and Savory J. Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J. Neurosci. Res. 71 (2003) 853-862
11. Goodenough S., Conrad S., Skutella T., and Behl C. Inactivation of glycogen synthase kinase-3β protects against kainic acid-induced neurotoxicity in vivo. Brain Res. 1026 (2004) 116-125
12. Hongisto V., Smeds N., Brecht S., Herdegen T., Courtney M.J., and Coffey E.T. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol. Cell. Biol. 23 (2003) 6027-6036
13. Jin N., Kovacs A.D., Sui Z., Dewhurst S., and Maggirwar S.B. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 48 (2005) 576-583
14. Jope R.S., and Johson G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
15. Jope R.S., Yuskaitis C.J., and Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32 (2007) 577-595
16. King T.D., and Jope R.S. Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 16 (2005) 597-601
17. Lai J.S., Zhao C., Warsh J.J., and Li P.P. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur. J. Pharmacol. 539 (2006) 18-26
18. Lee K.Y., Koh S.H., Noh M.Y., Park K.W., Lee Y.J., and Kim S.H. Glycogen synthase kinase-3beta activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells. Brain Res. 1129 (2007) 89-99
19. Linseman D.A., Cornejo B.J., Le S.S., Meintzer M.K., Laessig T.A., Bouchard R.J., and Heidenreich K.A. A myocyte enhancer factor 2D (MEF2D) kinase activated during neuronal apoptosis is a novel target inhibited by lithium. J. Neurochem. 85 (2003) 1488-1499
20. Liu Q., Xie F., Rolston R., Moreira P.I., Nunomura A., Zhu X., Smith M.A., and Perry G. Prevention and treatment of Alzheimer disease and aging: antioxidants. Mini Rev. Med. Chem. 7 (2007) 171-180
21. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., Vargas R.S., Kapczinski F., Portela L.V., Souza D.O., Salvador M., and Gentil V. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial minic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421 (2007) 33-36
22. Moreira P.I., Siedlak S.L., Aliev G., Zhu X., Cash A.D., Smith M.A., and Perry G. Oxidative stress mechanisms and potential therapeutics in Alzheimer disease. J. Neural Trans. 112 (2005) 921-932
23. Pallas M., and Camins A. Molecular and biochemical features in Alzheimer's disease. Curr. Pharm. Des. 12 (2006) 4389-4408
24. Petersen R.B., Nunomura A., Lee H.G., Casadesus G., Perry G., Smith M.A., and Zhu X. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J. Alzheimer's Dis. 11 (2007) 143-152
25. Schafer M., Goodenough S., Moosmann B., and Behl C. Inhibition of glycogen synthase kinase 3β is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res. 1005 (2004) 84-89
26. Shao L., Young L.T., and Wang J.F. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol. Psychiatry 58 (2005) 879-884
27. Verdaguer E., Jiménez A., Canudas A.M., Jorda E.G., Sureda F.X., Pallas M., and Camins A. Inhibition of cell cycle pathway by flavopiridol promotes survival of cerebellar granule cells after an excitotoxic treatment. J. Pharmacol. Exp. Ther. 308 (2004) 609-616
28. Wang J.F., Shao L., Sun X., and Young L.T. Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons. J. Neurochem. 88 (2004) 1477-1484
29. 2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci. Lett. 367 (2004) 355-359
30. Yeste M., Alvira D., Verdaguer E., Tajes M., Folch J., Rimbau V., Pallas M., and Camins A. Evaluation of acute antiapoptotic effects of Li(+) in neuronal cell cultures. J. Neural Trans. 114 (2007) 405-416
31. Yeste-Velasco M., Folch J., Trullas R., Abad M.A., Enguita M., Pallas M., and Camins A. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology 53 (2007) 295-307
32. Youdim M.B., and Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46 (2004) 1130-1140
33. Zhong J., Yang X., Yao W., and Lee W. Lithium protects ethanol-induced neuronal apoptosis. Biochem. Biophys. Res. Commun. 350 (2006) 905-910
34. Zhong J., and Lee W.H. Lithium: a novel treatment for Alzheimer's disease?. Expert Opin. Drug Saf. 6 (2007) 375-383
35. Zhu X., Perry G., Moreira P.I., Aliev G., Cash A.D., Hirai K., and Smith M.A. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J. Alzheimer's Dis. 9 (2006) 147-153
36. Zhu X., Su B., Wang X., Smith M.A., and Perry G. Causes of oxidative stress in Alzheimer disease. Cell. Mol. Life Sci. 64 (2007) 2202-2210